Meaningful Symptomatic Change in Patients With Myelofibrosis From the SIMPLIFY Studies

This publication has 17 references indexed in Scilit:

• Symptomatic benefit of momelotinib in patients with myelofibrosis: Results from the SIMPLIFY phase III studies
  Cancer Medicine, 2023
• MPN-303: Longitudinal and Individual Symptom Analyses from the SIMPLIFY-1 Study Demonstrate Clinically Comparable Symptomatic Benefit of Momelotinib to Ruxolitinib in JAK Inhibitor-Naive Myelofibrosis Patients
  Clinical Lymphoma Myeloma and Leukemia, 2021
• Addressing Bias in Responder Analysis of Patient-Reported Outcomes
  Therapeutic Innovation & Regulatory Science, 2021
• Epidemiology of the Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms
  Hematology/Oncology Clinics of North America, 2021
• Primary myelofibrosis: 2021 update on diagnosis, risk‐stratification and management
  American Journal of Hematology, 2020
• Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis
  JAMA Oncology, 2018
• Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial
  The Lancet Haematology, 2018
• Approach to MPN Symptom Assessment
  Current Hematologic Malignancy Reports, 2017
• Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis
  JAMA Oncology, 2015
• The Myelofibrosis Symptom Assessment Form (MFSAF): An evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis
  Leukemia Research, 2009